Zacks analysis identifies Smith & Nephew (SNN) as a superior value option compared to Stryker (SYK) within the Medical - Products sector. SNN holds a Zacks Rank #2 (Buy) against SYK's #3 (Hold), reflecting a stronger earnings outlook and more favorable valuation metrics. Specifically, SNN exhibits a lower forward P/E of 18.55 versus SYK's 27.91, a PEG ratio of 1.02 versus 2.71, and a P/B ratio of 2.92 versus 6.8, culminating in SNN's Value grade of B compared to SYK's D.
Based on a comparative value analysis within the Medical - Products sector, Smith & Nephew (SNN) presents a more compelling value proposition than Stryker (SYK). This assessment is supported by SNN's superior Zacks Rank of #2 (Buy) versus SYK's #3 (Hold), indicating a stronger trend of positive earnings estimate revisions for SNN. The valuation disparity is stark across multiple metrics: SNN trades at a forward P/E of 18.55, significantly lower than SYK's 27.91. Furthermore, SNN's PEG ratio of 1.02 suggests its stock price is reasonably aligned with its expected earnings growth, while SYK's PEG of 2.71 points to a substantial premium relative to its growth outlook. The value case for SNN is reinforced by its Price-to-Book (P/B) ratio of 2.92, which is less than half of SYK's 6.8. These quantitative factors culminate in SNN achieving a 'B' grade for Value, whereas SYK receives a 'D', solidifying the conclusion that SNN currently offers more attractive valuation characteristics for value-focused investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
